ChemicalBook >> CAS DataBase List >>Baloxavir marboxil

Baloxavir marboxil

CAS No.
1985606-14-1
Chemical Name:
Baloxavir marboxil
Synonyms
Xofluza;S-033188;(3R)-2-[(11S)-7,8-difluoro-6,11-dihydrobenzo[c][1]benzothiepin-11-yl]-9,12-dioxo-5-oxa-1,2,8-triazatricyclo[8.4.0.03,8]tetradeca-10,13-dien-11-yl]oxymethyl methyl carbonate;CS-2794;S-033188;XOFLUZA;Baloxavirmarboxi;aloxavir marboxil;2'S)-Folinic acid;Baloxavir marboxil;Baoxavir Marboxdil
CBNumber:
CB63361382
Molecular Formula:
C27H23F2N3O7S
Molecular Weight:
571.55
MDL Number:
MFCD31619272
MOL File:
1985606-14-1.mol
Last updated:2024-04-25 17:59:01

Baloxavir marboxil Properties

Boiling point 712.8±70.0 °C(Predicted)
Density 1.57±0.1 g/cm3(Predicted)
storage temp. Sealed in dry,Store in freezer, under -20°C
solubility DMSO:45.0(Max Conc. mg/mL);78.73(Max Conc. mM)
form A crystalline solid
pka -1.46±0.40(Predicted)
InChIKey HKVHAHZGMLTCDW-BWFGELNCSA-N
SMILES C(O)(=O)OC(OC1=C2N(C=CC1=O)N([C@H]1C3=CC=C(F)C(F)=C3CSC3=CC=CC=C31)[C@]1([H])COCCN1C2=O)C
FDA UNII 505CXM6OHG
NCI Drug Dictionary baloxavir marboxil
ATC code J05AX25

SAFETY

Risk and Safety Statements

Symbol(GHS)  GHS hazard pictograms
GHS07
Signal word  Warning
Hazard statements  H302-H315-H319-H335
Precautionary statements  P261-P280-P301+P312-P302+P352-P305+P351+P338

Baloxavir marboxil price

Manufacturer Product number Product description CAS number Packaging Price Updated Buy
ChemScene CS-0030527 Baloxavirmarboxil 98.94% 1985606-14-1 5mg $90 2021-12-16 Buy
ChemScene CS-0030527 Baloxavirmarboxil 98.94% 1985606-14-1 10mg $150 2021-12-16 Buy
AK Scientific 4327EH Baloxavirmarboxil 1985606-14-1 25mg $151 2021-12-16 Buy
ChemScene CS-0030527 Baloxavirmarboxil 98.94% 1985606-14-1 25mg $280 2021-12-16 Buy
ChemScene CS-0030527 Baloxavirmarboxil 98.94% 1985606-14-1 50mg $450 2021-12-16 Buy
Product number Packaging Price Buy
CS-0030527 5mg $90 Buy
CS-0030527 10mg $150 Buy
4327EH 25mg $151 Buy
CS-0030527 25mg $280 Buy
CS-0030527 50mg $450 Buy

Baloxavir marboxil Chemical Properties,Uses,Production

Description

Baloxavir marboxil is an antiviral drug developed by Shionogi Co., a Japanese pharmaceutical company and Roche for the treatment of influenza A and influenza B infections. The drug was initially approved for use in Japan in February 2018 and approved by the FDA on October 24, 2018 for the treatment of acute uncomplicated influenza in patients 12 years of age and older who have been symptomatic for no more than 48 hours Label. Baloxavir marboxil, a cap-endonuclease inhibitor, has a unique mechanism of action when compared to the currently existing neuraminidase inhibitor drug class used to treat influenza infections.

Pharmacokinetics

Baloxavir marboxil is a selective inhibitor of influenza cap-dependent endonuclease which prevents polymerase function and therefore influenza virus mRNA replication 5, 3. It has shown therapeutic activity against influenza A and B virus infections, including strains resistant to current antiviral agents 1. This drug inhibits an enzyme required for viral replication, thus rapidly treating flu virus infection 5, Label and alleviating the symptoms associated with infection. A single dose of this agent was shown to be superior to placebo in relieving influenza symptoms and superior to both oseltamivir and placebo drug in virologic outcomes (marked by decreased viral load).

Uses

Baloxavir marboxil is an influenza medication, an antiviral,that is taken as a single dose tablet,by mouth, by individuals that are 12 years of age or older,that have presented symptoms of this infection for no more than 48 hours.The efficacy of baloxavir marboxil administered after 48 hours has not been tested.

Contraindications

Baloxavir marboxil should not be co-administered with dairy products, calcium-fortified beverages, or laxatives, antacids, or oral supplements containing calcium, iron, magnesium, selenium, aluminum or zinc.

Metabolism

Baloxavir marboxil is a prodrug that is converted by hydrolysis to baloxavir, the active form that exerts anti-influenza virus activity Label.

Uses

Baloxavir Marboxil is a prodrug of S-033447, which is an inhibitor of the cap-dependent endonuclease of influenza A and B viruses.

Preparation

The synthesis of baloxavir marboxil involved the following steps: The coupling of the 1-R and 2 fragments was carried out under dehydration conditions of 1-propanephosphonic anhydride (T3P) and methanesulfonic acid at 70 °C to obtain protected baloxavir 19. Compound 19 was then reacted with 0.6 equivalents of PhBr and K2CO3. Debenzylation was then carried out using LiCl in CH3CONMe2 to give baloxavir acid in 94% yield. In the final step for the preparation of the prodrug, baloxavir acid was reacted with chloromethyl methyl carbonate in dimethylacetamide in 93% yield to form baloxavir marboxyl.
The reaction mechanism for the final step for the synthesis of baloxavir marboxil(BXM)
The reaction mechanism for the final step for the synthesis of baloxavir marboxil(BXM).

brand name

XOFLUZA? (baloxavir marboxil)

Biological Activity

Baloxavir marboxil is a prodrug that is metabolised to the active form baloxavir acid also known as S-033447. S-033447 is a small molecule inhibitor of the cap-dependent endonuclease of influenza A and B viruses. It has shown nanomolar antiviral activity against influenza A and B viruses in vitro. In murine models of seasonal influenza and avian influenza A(H5N1) or A(H7N9), orally administered baloxavir showed a rapid reduction in pulmonary viral loads and decreased mortality. Baloxavir significantly reduced the time for alleviation of symptoms and reduced virus titres at 24 and 48 hours post-treatment at three different doses (10 mg, 20 mg and 40 mg) in a phase II study with patients experiencing uncomplicated influenza.

Mechanism of action

Baloxavir marboxil is an influenza therapeutic agent, specifically, an enzyme inhibitor targeting the influenza virus' cap-dependent endonuclease activity, one of the activities of the virus polymerase complex. In particular, it inhibits a process known as cap snatching, by which the virus derives short, capped primers from host cell RNA transcripts, which it then uses for polymerase-catalyzed synthesis of its needed viral mRNAs. A polymerase subunit binds to the host pre-mRNAs at their 5' caps, then the polymerase's endonuclease activity catalyzes its cleavage "after 10–13 nucleotides". As such, its mechanism is distinct from neuraminidase inhibitors such as oseltamivir and zanamivir.

Side effects

Common side effects following the single dose administration of baloxavir marboxil include diarrhea, bronchitis, common cold, headache, and nausea. Adverse events were reported in 21% of people who received baloxavir, 25% of those receiving placebo, and 25% of oseltamivir.

References

[1] HUGHES* D L. Review of the Patent Literature: Synthesis and Final Forms of Antiviral Drugs Tecovirimat and Baloxavir Marboxil[J]. Organic Process Research & Development, 2019, 23 7: 1298-1307. DOI:10.1021/acs.oprd.9b00144.
[2] ANDOYOSHINORI. Pharmacokinetic and pharmacodynamic analysis of baloxavir marboxil, a novel cap-dependent endonuclease inhibitor, in a murine model of influenza virus infection.[J]. Journal of Antimicrobial Chemotherapy, 2021, 76 1: 189-198. DOI:10.1093/jac/dkaa393.
[3] YANGTIANRUI. Baloxavir Marboxil: The First Cap-Dependent Endonuclease Inhibitor for the Treatment of Influenza.[J]. Annals of Pharmacotherapy, 2019, 53 7: 754-759. DOI:10.1177/1060028019826565.
[4] Chemical Structure and Synthesis of Baloxavir Marboxil, A Novel Endonuclease Inhibitor For The Treatment Influenza : An Overview

Global( 282)Suppliers
Supplier Tel Email Country ProdList Advantage
Heading (Nanjing)Pharmtechnologies Co., Ltd.
+86-25-58467899-832 +86-13382406280 liucheng@headingpharm.com China 46 58
Hubei Ipure Biology Co., Ltd
+8613367258412 ada@ipurechemical.com China 10326 58
Beijing Mesochem Technology Co.,Ltd
+8613651027935 rachel@mesochem.com China 191 58
Porton Pharma Solutions Ltd.
China 56 58
Dorne Chemical Technology co. LTD
+86-13583358881 +86-18560316533 Ethan@dornechem.com China 294 58
shandong perfect biotechnology co.ltd
+86-53169958659; +8618596095638 sales@sdperfect.com China 294 58
Hangzhou ICH Biofarm Co., Ltd
+undefined8613073685410 sales@ichemie.com China 985 58
Hebei Xinsheng New Material Technology Co., LTD.
+86-16632316109 xinshengkeji@xsmaterial.com China 1100 58
Shandong Hanjiang Chemical Co., Ltd
+86-0533-2066820 +8618369939125 hanson@sdhanjiang.com China 1527 58
Shaanxi TNJONE Pharmaceutical Co., Ltd
+8618740459177 sarah@tnjone.com China 893 58

Related articles

Related Qustion

View Lastest Price from Baloxavir marboxil manufacturers

Image Update time Product Price Min. Order Purity Supply Ability Manufacturer
Baloxavir marboxil pictures 2024-04-27 Baloxavir marboxil
1985606-14-1
US $10.00 / ASSAYS 1ASSAYS 99% 10 ton Dorne Chemical Technology co. LTD
Baloxavir Marboxil pictures 2024-04-25 Baloxavir Marboxil
1985606-14-1
US $0.00 / kg 1kg 99% 1000kg Shaanxi TNJONE Pharmaceutical Co., Ltd
Baloxavir marboxil pictures 2024-04-12 Baloxavir marboxil
1985606-14-1
US $0.00 / kg 1kg 0.99 10T Shandong Hanjiang Chemical Co., Ltd

Baloxavir marboxil Spectrum

CS-2794 S-033188;XOFLUZA aloxavir marboxil PubChem ID: 124081896 Baloxavir marboxil baloxavir marboxil S-033188 Baloxavir Impurity 9 Carbonic acid, [[(12aR)-12-[(11S)-7,8-difluoro-6,11-dihydrodibenzo[b,e]thiepin-11-yl]-3,4,6,8,12,12a-hexahydro-6,8-dioxo-1H-[1,4]oxazino[3,4-c]pyrido[2,1-f][1,2,4]triazin-7-yl]oxy]methyl methyl ester Baoxavir Marboxdil N - [(s) - (2,3,4,5,6-pentafluorophenoxy) phenoxyphosphoryl] - L-alanine isopropyl ester (pentafluoroside chain) Baloxavir marboxil (BXM, S033188) 1985606-14-1 Baloxavir marboxil 2'S)-Folinic acid S-033188 Xofluza Baloxavir marboxil1 (3R)-2-[(11S)-7,8-difluoro-6,11-dihydrobenzo[c][1]benzothiepin-11-yl]-9,12-dioxo-5-oxa-1,2,8-triazatricyclo[8.4.0.03,8]tetradeca-10,13-dien-11-yl]oxymethyl methyl carbonate (((R)-12-((S)-7,8-Difluoro-6,11-dihydrodibenzo[b,e]thiepin-11-yl)-6,8-dioxo-3,4,6,8,12,12a-hexahydro-1H-[1,4]oxazino[3,4-c]pyrido[2,1-f][1,2,4]triazin-7-yl)oxy)methyl methyl carbonate {[(3R)-2-[(2S)-12,13-difluoro-9-thiatricyclo[9.4.0.03,?]pentadeca-1(11),3(8),4,6,12,14-hexaen-2-yl]-9,12-dioxo-5-oxa-1,2,8-triazatricyclo[8.4.0.03,?]tetradeca-10,13-dien-11-yl]oxy}methyl methyl carbonate Baloxavirmarboxi IBaloxavir marboxi Baloxavir marboxil API Baloxavir Marboxil In-House baloxavirmarboxil impurities ({(12aR)-12-[(11S)-7,8-Difluoro-6,11-dihydrodibenzo[b,e]thiepin-11-yl]-6,8-dioxo-3,4,6,8,12,12a-hexahydro-1H-[1,4]oxazino[3,4-c]pyrido[2,1-f][1,2,4]triazin-7-yl}oxy)methyl methyl carbonate 1985606-14-1 985606-14-1 1986605-59-1 C27H23F2N3O7S API 1985606-14-1